Navigation Links
Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Date:2/12/2008

econciled" amounts related to Net (loss)/income available to common shareholders and diluted (loss)/earnings per common share. "As Reconciled" amounts exclude the effects of purchase accounting adjustments, acquisition related items and other specified charges or benefits.

"As Reconciled" amounts related to Net (loss)/income available to common shareholders and diluted (loss)/earnings per common share are non-U.S. GAAP measures used by management in evaluating the performance of Schering-Plough's overall business. The effects of purchase accounting adjustments, acquisition related items and other specified charges or benefits have been excluded from net (loss)/income available to common shareholders and diluted (loss)/earnings per common share as management of Schering-Plough does not consider these charges to be indicative of continuing operating results. Schering-Plough believes that these "As Reconciled" performance measures contribute to a more complete understanding by investors of the overall results of the company and enhances investor understanding of items that impact the comparability of results between fiscal periods. Net (loss)/income available to common shareholders and diluted (loss)/earnings per common share, as reported, are required to be presented under U.S. GAAP.

Three months ended December 31, 2007

Purchase Acquisition- Other

As Accounting Related Specified As

Reported Adjustments Items Items Reconciled

Net sales $3,724 $ - $ - $ - $3,724

Cost of sales 1,566 (326) - - 1,240

Selling, general

and administrative 1,634 - - - 1,634

Research and development 855 - - (21) 834

Acquired in-process

researc
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
2. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
5. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
6. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
9. Schering-Plough Completes Acquisition of Organon BioSciences
10. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
11. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... TOLEDO recently announced that a free webinar, &l... At-Line Particle Characterization”, will be...the application of in situ particle characterizati...imize a series of roller compaction runs while var...ion forces. , (PRWEB) Nov...
(Date:11/19/2009)...able to charge their cell phones and other persona...discovery made by UC San Diego engineers could lea...uld do just this. , In recent research, publish..., a professor in the UCSD Department of Mechanical...udent Mark Hoefer, have found that artificially in...
(Date:11/19/2009)...wswire-FirstCall/ -- Omeros Corporation (Nasdaq: ... for the third quarter ended September 30, 2009. F...os reported a net loss of $3.9 million, or $1.34 p...n, or $2.54 per share, for the same period in 2008...e Company reported a net loss of $15.5 million, or...
(Date:11/19/2009)...Md., Nov. 19 Spherix Inc...hnology for diabetes therapy, and a provider of te..., supplement, biotechnology and pharmaceutical com...eported $6.3 million registered direct placement t...ts common stock and warrants to purchase up to 1,1...
Breaking Biology Technology:Roller Compaction Process Optimization Using At-Line Particle Characterization 2Nanotube defects equal better energy and storage systems 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3
... of Gene Expression Signatures Derived by COXEN Al...to Current Treatments, OMAHA, Neb., and CHARLOTTE...ansgenomic (OTC Bulletin Board: TBIO) today announ...olecular diagnostic test which will guide,clinicia...ts for ovarian,cancer. The new test will be powere...
...t. 16 Intact Medical Corporation, an,emerging lea...invasive,systems for the diagnosis and removal of ...ed U.S. Food and Drug Administration (FDA) 510(k),...version of the Company,s,already FDA approved wand...,System (BLES). The Company expects to begin marke...
...6 Ardea Biosciences, Inc.,(Nasdaq: RDEA ) announ...l,data on RDEA594, its lead product candidate for ... on RDEA119,its lead mitogen-activated ERK kinase,...associated with gouty,arthritis, at the 2008 Ameri...CR) / Association of Rheumatology Health Professio...
Other Biology Technology:Transgenomic Announces Partnership With Key Genomics for Ovarian Cancer Assay to Guide Therapeutic Options 2Transgenomic Announces Partnership With Key Genomics for Ovarian Cancer Assay to Guide Therapeutic Options 3Transgenomic Announces Partnership With Key Genomics for Ovarian Cancer Assay to Guide Therapeutic Options 4Intact Medical Corporation's Intact(R) Excise XL Receives 510(K) Marketing Clearance from the FDA 2Ardea Biosciences to Present Data on Gout and Inflammation Programs at the 2008 ACR/ARHP Annual Scientific Meeting 2Ardea Biosciences to Present Data on Gout and Inflammation Programs at the 2008 ACR/ARHP Annual Scientific Meeting 3
(Date:11/20/2009)..., , NJIT researchers are at work on many scientif...ce Foundation has recently provided support that t...of the following investigators under the American ...researchers have been awarded grants for investiga...ished professor of physics, will enhance the capab...
(Date:11/20/2009)..., Researchers are invited to contribute their abs...(IOF WCO ECCEO10), the largest global meeting dev...itis research and patient care. The Congress will ... Beginning today, abstracts can be submitted onlin...ission deadline is February 4, 2010. , IOF and E...
(Date:11/20/2009)..., With the introduction of a single bacterial gen... Technology in the Netherlands achieved three impr...l waste material: ,More ethanol, less acetate and ... week the invention was published in the scientifi.... , Car fuel , Bioethanol is made by the yea...
Breaking Biology News(10 mins):NJIT receives NSF funding to improve Big Bear Telescope, study solar energy 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 3Delft breakthrough in bioethanol production from agricultural waste 2Joint research into an enzyme that causes genetic diseases 9486 1Pinhead size worms + robot 3D new antibiotics 9481 1Addrenex Pharmaceuticals Announces Licensing Agreement With Dream Pharma 53737 1Addrenex Pharmaceuticals Announces Licensing Agreement With Dream Pharma 53737 2
...c health: Bioengineering researchers from the EPFL...nted a nanoparticle that can deliver vaccines more...action of the cost of current vaccine technologies...tember 16 in the journal Nature Biotechnology, the... combination of nanotechnology and chemistry that ...
...ed in Nature Genetics on Sunday 16 September 2007 ... to be due to genetic variation in regions that co...s that specify the protein code. , This surprisin...Sanger Institute of the activity of almost 14,000 ...Project. The authors looked at 2.2 million DNA seq...
...hers are among the leaders in a worldwide effort t...s in the laboratory and in the field with a techni...hat identifies an item at the grocery store, a DNA...gical species. , This month, scientists are gath...de of Life Conference (Sept. 17-21). They will dis...
Other Biology News:New nanoparticle vaccine is more effective but less expensive 2New nanoparticle vaccine is more effective but less expensive 3The importance of gene regulation for common human disease 2Smithsonian scientists help lead effort to 'barcode' world's species 2Smithsonian scientists help lead effort to 'barcode' world's species 3
...EtBr Spin Columns provide a rapid and simple metho... (100 bp to 10 kb) from stained agarose gels or Et...rom an agarose gel and loaded into the spin column...ies of membranes and filters that hold agarose and...
...nables efficient extraction of DNA fragments from ...he procedure uses GelMelt solution to dissolve the... silica membrane in a spin column format. After a ...buffer. Each spin column can bind up to 20 g DNA. ...
StemSep Anti-Hu HLA-DR Tetramer, 200 uL from StemCell Technologies, Inc.
...ed by end-users to be "a delight to use" as it inc... electronic imaging. With its ergonomic design and...nd can easily be accommodated in a busy lab enviro...nary Colour Corrected Infinity System and infinity...
Biology Products: